NeuroMab™ Anti-Transferrin Receptor BBB Shuttle Antibody(NRZP-1022-ZP3956)

Figure 1 depicts FACS analysis of mouse hybridoma parental clone supernatants binding to human and macaque TfR transiently expressed in 293 cells in the presence of 1 μM human holo-Tf.

Figure 2 depicts the binding of hu7A4.v15, hu15G11.v5 and hu7G7.v1 to huTfR in the presence of 6.3 μM holo-Tf.

Figure 3 depicts the results of HFE-HuTfR binding and HFE blocking assays

Figure 4 depicts the results of hematology sampling performed during the study.

Figure 5 shows the individual and group mean values of anti-TfR1/BACE1, anti-TfR2/BACE1, anti-gD and anti- BACE1 ratio versus time in monkeys

Figure 6 depicts the pharmacokinetic properties of anti-TfR1/BACE1, anti-Tfr52A/BACE1 and anti-TfR53A/BACE1.

Figure 7 depicts the pharmacokinetic properties of murine IgG2a anti-TfRD/BACE1 and anti-gD antibodies with Fc effector function LALAPG mutations.

Figure 8 depicts total and immature reticulocyte counts in mice 24 hours after administration of a 50 mg/kg dose of murine IgG2a anti-TfRD/BACE1 and anti-gD antibodies with Fc effector function LALAPG mutations.

Figure 9 depicts the total reticulocyte count in mice 24 hours after administration of 50 mg/kg doses of anti-TfR52A/BACE1 (N297G), anti-TfR52A/BACE1 (LALAPG), anti-TfR52A/BACE1 (LALAPG/YTE), Antibody to TfR52A/BACE1 (LALAPG/AI) in human transferrin receptor knock-in mice.

Figure 10 depicts the results of experiments evaluating the effects of effector functional status on ADCC activity of anti-TfR/gD, anti-TfR/BACE1 (N297G), anti-TfR/BACE1 (LALAPG), anti-TfR/BACE1 (N297G) /434A/ 436I) and anti-TfR/BACE1 (LALAPG/YTE) antibodies in primary human myelomonocytic or human erythroblast lineages.

Figure 11 depicts a competition assay between 15G11v.5 and anti-TfRC12.